Uric Acid: Gout, Kidney Stones, and What High Levels Really Mean

Uric acid is the end product of purine metabolism, the leftover when your body breaks down DNA, RNA, and the purines you eat (red meat, organ meats, certain seafood, beer). Most mammals have an enzyme called uricase that breaks it down further into a soluble compound. Humans lost the working version of that gene millions of years ago. The trade-off was higher plasma antioxidant capacity at the cost of running close to the solubility ceiling of urate in body fluids.

The solubility limit at body temperature and physiologic pH is about 6.8 mg/dL. Above that, monosodium urate crystals can drop out of solution, especially in cooler peripheral joints (the first metatarsophalangeal joint, the classic site of acute gout) and in the kidneys (uric acid stones).

Plasma uric acid reflects the balance between production (purine breakdown) and excretion (about 70% renal, 30% gut). Most hyperuricemia comes from under-excretion, not overproduction. The kidney is the dominant regulator, and genetics set its reabsorption setpoint. That is why uric acid is one of the more familial lab values.

One paradox worth knowing: uric acid is a meaningful antioxidant in plasma, but once it enters cells or crystallizes, it is pro-inflammatory. Whether that pro-inflammatory side meaningfully drives cardiovascular disease and CKD in asymptomatic patients is genuinely contested.

Standard adult reference ranges:

• Men: 3.4 to 7.0 mg/dL.
• Women: 2.4 to 6.0 mg/dL (lower because estrogen promotes urate excretion; values drift toward male levels after menopause).
• Children: 2.0 to 5.5 mg/dL.

For people with established gout, the relevant number is not the lab reference range. It is the saturation threshold of urate. Treatment targets:

• Below 6.0 mg/dL for most patients with gout (ACR and EULAR).
• Below 5.0 mg/dL for tophi, frequent flares, or chronic tophaceous gout. The lower target encourages crystal dissolution.

Source: ACR 2020, EULAR 2017 gout management guidelines.

Asymptomatic hyperuricemia

The most common situation by far: a uric acid above the reference range with no gout, no kidney stones, no symptoms. About 20% of adults fit this picture at any given time. Most major guidelines do not recommend pharmacologic treatment. The annual risk of progressing to gout is low at most levels, and trials of urate-lowering therapy in asymptomatic hyperuricemia have not shown clear cardiovascular or renal benefit. Lifestyle changes are reasonable. Daily allopurinol "just in case" generally is not.

This is genuinely debated. Some cardiology and nephrology groups argue the cumulative pro-inflammatory effect adds up over decades. The current evidence does not yet support the change in practice. So most internists watch and wait, treat the metabolic syndrome around it, and pull the drug trigger only when symptoms appear.

Gout

The clinical syndrome: sudden severe joint pain, redness, and warmth, classically in the great toe (podagra), classically peaking within hours and resolving over days. Higher uric acid means higher risk. Above 9.0 mg/dL the annual gout incidence is about 5%, an order of magnitude higher than at 6.0. Diagnosis is ideally confirmed by joint aspiration showing negatively birefringent monosodium urate crystals, but in a textbook attack with a known history, empirical treatment is reasonable.

Kidney stones

Uric acid stones account for about 10% of all kidney stones and form preferentially in acidic urine. People with metabolic syndrome and type 2 diabetes are especially prone because their urine pH runs low. Hyperuricemia plus a history of stones is one of the clearer indications for urate-lowering therapy.

Common causes of high uric acid

• Genetics. Roughly 60% of the variance in uric acid is heritable.
• Diet. Red meat, organ meats, certain seafood (anchovies, sardines, mackerel), high-fructose foods and drinks (especially sugar-sweetened soda), and alcohol. Beer is the worst because of both ethanol and guanosine content.
• Diuretics. Thiazides and loop diuretics. One of the most common iatrogenic causes.
• Chronic kidney disease. Reduced excretion raises plasma urate.
• Metabolic syndrome and obesity. Insulin resistance reduces renal urate excretion.
• Tumor lysis syndrome. Massive cell turnover after chemotherapy floods the body with purines. Medical emergency, needs rasburicase or aggressive allopurinol.
• Other medications. Low-dose aspirin (paradoxically raises urate), niacin, cyclosporine, tacrolimus, levodopa, ethambutol, pyrazinamide.
• Hypothyroidism, hyperparathyroidism, lead exposure, psoriasis with high cell turnover.

Treatment of symptomatic hyperuricemia

For gout, kidney stones, or chronic kidney disease with hyperuricemia:

• Allopurinol. First-line xanthine oxidase inhibitor. Start low (100 mg/day, lower in CKD), titrate every 2 to 4 weeks toward target. Dose can go to 800 mg/day if needed. HLA-B*5801 testing is recommended before starting in high-risk populations (Han Chinese, Korean, Thai) due to severe cutaneous adverse reaction risk.
• Febuxostat. Alternative xanthine oxidase inhibitor for allopurinol intolerance or non-response. Note the FDA boxed warning on cardiovascular mortality in patients with established cardiovascular disease.
• Probenecid. Uricosuric. Useful in under-excretors with normal renal function and no stone history.
• Pegloticase. Recombinant uricase for refractory tophaceous gout. IV infusion, third-line.
• Lifestyle. Weight loss, reduced alcohol (especially beer), reduced fructose intake, hydration, low-fat dairy. Effects are modest (typically 1 to 1.5 mg/dL) but additive to drug therapy.

Low uric acid is rarely a clinical worry but can occasionally point to a real problem:

• Severe liver disease. The liver is required for purine breakdown to urate.
• Fanconi syndrome. Generalized proximal tubular dysfunction wastes urate, along with amino acids, glucose, phosphate, and bicarbonate.
• SIADH. Hyponatremia from inappropriate ADH is often accompanied by low uric acid.
• Medications. High-dose salicylates, allopurinol overdose, losartan, fenofibrate, and SGLT2 inhibitors all lower uric acid.
• Xanthinuria. Rare inherited xanthine oxidase deficiency.
• Pregnancy. Plasma volume expansion lowers concentration. In preeclampsia the level paradoxically climbs.

Low uric acid by itself is not treated.

Single readings swing 1 to 2 mg/dL with diet, hydration, and recent illness. A reading of 7.4 in someone who usually runs 6.5 might just be a steak dinner and a margarita the night before. Clinical decisions almost always need either a confirmatory second reading or a trend.

Useful patterns:

• During an acute gout flare. Uric acid often drops 1 to 2 mg/dL because urate is being deposited as crystals out of solution. A "normal" uric acid during an acute attack does not rule out gout.
• Starting urate-lowering therapy. Paradoxically increases flare risk for the first 6 months as crystals shift in and out of joints. This is why initiation is paired with prophylactic colchicine or a low-dose NSAID.
• Long-term gout management. Sustained uric acid below 6.0 (or below 5.0 with tophi) over years allows crystals to dissolve and tophi to shrink. Stopping therapy after years of good control usually leads to gradual return of hyperuricemia.
• Slow drift upward. Common with weight gain, a new diuretic, declining renal function, or developing metabolic syndrome.

• Acute gout flare. Treat the flare with NSAIDs, colchicine, or steroids. Do not start or stop urate-lowering therapy during an acute attack. Plan urate-lowering therapy after the flare resolves.
• Two or more gout flares per year, tophi, or uric acid stones. Start urate-lowering therapy. Target under 6.0 mg/dL (under 5.0 with tophi).
• Asymptomatic uric acid above 9 mg/dL. High enough that progression to symptomatic gout is more likely than not. Lifestyle changes and diuretic review are reasonable. Pharmacologic treatment is individualized, not reflex.
• Tumor lysis syndrome. Rapidly rising uric acid after chemotherapy is a medical emergency. Rasburicase, aggressive hydration, renal monitoring.
• New hyperuricemia after starting a thiazide. Common and predictable. Usually does not need new therapy unless gout actually occurs. Consider whether the diuretic can be switched.

• Creatinine and BUN. Kidney function is the dominant regulator of uric acid. Elevated creatinine often explains hyperuricemia and changes drug dosing.
• Metabolic panel. Overall renal and electrolyte status.
• Fasting glucose and HbA1c. Metabolic syndrome and insulin resistance accompany hyperuricemia and explain a substantial fraction of cases.
• Triglycerides and HDL cholesterol. Additional metabolic syndrome markers. Cluster with hyperuricemia.
• 24-hour urine uric acid. Distinguishes overproducers from under-excretors. Useful when choosing between allopurinol and a uricosuric.
• CBC. Needed to monitor for hematologic causes of high cell turnover and for allopurinol side effects.
• HLA-B*5801. Pre-allopurinol genetic screening in high-risk populations.